These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 9196608

  • 1. Growth response and levels of growth factors after two years growth hormone treatment are similar for a once and twice daily injection regimen in girls with Turner syndrome. (Dutch Working Group on Growth Hormone).
    van Teunenbroek A, de Muinck Keizer-Schrama S, Stijnen T, Waelkens J, Wit JM, Vulsma T, Gerver WJ, Reeser H, Delemarre-van de Waal H, Jansen M, Drop S.
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):451-9. PubMed ID: 9196608
    [Abstract] [Full Text] [Related]

  • 2. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Delemarre-van de Waal HA, Vulsma T, Wit JM, Rouwé CW, Reeser HM, Gosen JJ, Rongen-Westerlaken C, Drop SL.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4013-21. PubMed ID: 8923853
    [Abstract] [Full Text] [Related]

  • 3. Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections. Dutch Advisory Group on Growth Hormone.
    Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, van Teunenbroek A, Hokken-Koelega AC, Waelkens JJ, Massa GG, Vulsma T, Gerver WJ, Reeser HM, Delemarre-van de Waal HE, Jansen M, Drop SL.
    Arch Dis Child; 1999 Jan; 80(1):36-41. PubMed ID: 10325756
    [Abstract] [Full Text] [Related]

  • 4. Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A, de Muinck Keizer-Schrama SM, Stijnen T, Mouton JW, Blum WF, Mercado M, Baumann G, Drop SL.
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):77-84. PubMed ID: 7688672
    [Abstract] [Full Text] [Related]

  • 5. Carbohydrate metabolism during growth hormone treatment and after discontinuation of growth hormone treatment in girls with Turner syndrome treated with once or twice daily growth hormone injections.
    Sas T, de Muinck Keizer-Schrama S, Aanstoot HJ, Stijnen T, Drop S.
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):741-7. PubMed ID: 10848879
    [Abstract] [Full Text] [Related]

  • 6. A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial.
    Sass TC, De Muinck Keizer-Schrama SM, Stijnen T, Asarfi A, Van Leeuwen WJ, Van Teunenbroek A, Van Rijn RR, Drop SL.
    Clin Endocrinol (Oxf); 2000 May; 52(5):531-6. PubMed ID: 10792330
    [Abstract] [Full Text] [Related]

  • 7. Serum growth hormone (GH)-binding protein and insulin-like growth factor-I levels in Turner's syndrome before and during treatment with recombinant human GH and ethinyl estradiol.
    Massa G, Bouillon R, Vanderschueren-Lodeweyckx M.
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1298-302. PubMed ID: 1430092
    [Abstract] [Full Text] [Related]

  • 8. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
    Bannink EM, van Doorn J, Stijnen T, Drop SL, de Muinck Keizer-Schrama SM.
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
    [Abstract] [Full Text] [Related]

  • 9. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens.
    van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwé CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL.
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1119-25. PubMed ID: 12629094
    [Abstract] [Full Text] [Related]

  • 10. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth.
    Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige MS, Wales JK, Clayton PE.
    Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450
    [Abstract] [Full Text] [Related]

  • 11. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults.
    Laursen T, Jørgensen JO, Christiansen JS.
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):337-43. PubMed ID: 7525120
    [Abstract] [Full Text] [Related]

  • 12. Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: effect of short- and long-term recombinant human growth hormone administration.
    Saggese G, Federico G, Cinquanta L.
    Pediatr Res; 1995 Jan; 37(1):106-11. PubMed ID: 7535419
    [Abstract] [Full Text] [Related]

  • 13. National Cooperative Growth Study substudy VI: the clinical utility of growth-hormone-binding protein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3 measurements.
    Attie KM, Julius JR, Stoppani C, Rundle AC.
    J Pediatr; 1997 Jul; 131(1 Pt 2):S56-60. PubMed ID: 9255230
    [Abstract] [Full Text] [Related]

  • 14. Influence of spontaneous or induced puberty on the growth promoting effect of treatment with growth hormone in girls with Turner's syndrome.
    Massa G, Maes M, Heinrichs C, Vandeweghe M, Craen M, Vanderschueren-Lodeweyckx M.
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):253-60. PubMed ID: 8458097
    [Abstract] [Full Text] [Related]

  • 15. Effect of growth hormone and 17beta-oestradiol treatment on metabolism and body composition in girls with Turner syndrome.
    Gravholt CH, Hjerrild BE, Naeraa RW, Engbaek F, Mosekilde L, Christiansen JS.
    Clin Endocrinol (Oxf); 2005 May; 62(5):616-22. PubMed ID: 15853835
    [Abstract] [Full Text] [Related]

  • 16. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
    Binder G, Baur F, Schweizer R, Ranke MB.
    J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
    [Abstract] [Full Text] [Related]

  • 17. Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study.
    Gravholt CH, Naeraa RW, Brixen K, Kastrup KW, Mosekilde L, Jørgensen JO, Christiansen JS.
    Pediatrics; 2002 Nov; 110(5):889-96. PubMed ID: 12415026
    [Abstract] [Full Text] [Related]

  • 18. Growth hormone treatment regimens in girls with Turner syndrome. Dutch Advisory Group on Growth Hormone.
    de Muinck Keizer-Schrama SM, Sas TC.
    Acta Paediatr Suppl; 1999 Dec; 88(433):126-9. PubMed ID: 10626563
    [Abstract] [Full Text] [Related]

  • 19. Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone.
    Haeusler G, Schmitt K, Blümel P, Plöchl E, Waldhör T, Frisch H.
    J Clin Endocrinol Metab; 1996 Feb; 81(2):536-41. PubMed ID: 8636264
    [Abstract] [Full Text] [Related]

  • 20. Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A, de Muinck Keizer-Schrama SM, Aanstoot HJ, Stijnen T, Hoogerbrugge N, Drop SL.
    Metabolism; 1999 Jan; 48(1):7-14. PubMed ID: 9920138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.